Familial Mediterranean fever

Area of Science:

• Genetics
• Immunology
• Rheumatology

Background:

• Familial Mediterranean fever (FMF) is the most common periodic fever syndrome.
• Characterized by recurrent polyserositis with symptoms like fever, abdominal pain, chest pain, and arthritis.
• An autosomal recessive disorder primarily affecting specific ethnic populations.

Purpose of the Study:

• To summarize key aspects of Familial Mediterranean fever (FMF).
• To highlight the genetic basis, clinical manifestations, and complications of FMF.
• To discuss current treatment strategies and associated risks.

Main Methods:

• Review of existing literature on Familial Mediterranean fever (FMF).
• Analysis of genetic factors, including the MEFV gene and genotype-phenotype correlations.
• Examination of FMF complications, particularly amyloidosis and associated genotypes.
• Evaluation of colchicine treatment efficacy and impact on disease progression.

Main Results:

• The MEFV gene, encoding pyrin, is identified as the cause of FMF.
• Genotype-phenotype correlations are not fully established.
• Amyloidosis is a severe complication, with the SAA1-alpha/alpha genotype linked to increased risk.
• Colchicine treatment reduces attack frequency/severity and prevents amyloidosis.
• Increased prevalence of vasculitides like Henoch-Schonlein purpura and polyarteritis nodosa in FMF patients.

Conclusions:

• Familial Mediterranean fever (FMF) is a significant genetic autoinflammatory disorder.
• Effective management with colchicine is crucial for preventing severe complications such as amyloidosis.
• Further research into genotype-phenotype correlations may refine personalized treatment approaches.